| ID | 1181 |
| Name of the vaccine | StaphVAX |
| Microbe | Bacteria |
| Disease name | Methicillin-Resistant Staphylococcus aureus (MRSA) |
| Name of bacteria | Staphylococcus aureus |
| Type of vaccine | Conjugate |
| Nucleic acid content | Circular DNA |
| Age | 18 years and older |
| Description of the vaccine | Bivalent S. aureus glycoconjugate vaccine. |
| Name of the manufacturer | Nabi Biopharmaceuticals |
| Name of the manufacturing country | NA |
| Year of manufacture | 2005 |
| Clinical Phase status | Clinical - Failed |
| Bacterial strain | Gram-positive bacteria.
|
| Efficacy | 64% through 32 weeks of follow-up and 57% through 40 weeks of follow-up. |
| Vaccine formulation | NA |
| Dosage | Two doses. |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | Treatment of infections in kidney patients receiving peritoneal dialysis and are prone to serious staphylococcal infections. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For Kidney failure, chronic. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 12054071 |
| Clinical trial number | NCT00071214 |
| Reference | https://www.fda.gov/media/109113/download |
| Other name | NA |
| Additional Links | NA
|